Inventiva Pharma

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and other diseases with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders, and oncology. The company's lead product candidate is lanifibranor, a pan-PPAR agonist currently in a pivotal Phase 3 clinical trial (NATiV3) for the treatment of MASH. Inventiva leverages a proprietary discovery engine and an extensive library of approximately 240,000 pharmacologically relevant molecules to develop differentiated therapies that target nuclear receptors, transcription factors, and epigenetic modulation.